抗青光眼新药Trusopt的临床疗效观察

目的 :探讨碳酸酐酶抑制剂的局部滴眼剂Trusopt对原发性开角型青光眼的临床疗效。方法 :选择 3 0名健康志愿者 ,随机分为对照组与试验组 ,分别采用 0 9%生理盐水和Trusopt1滴点眼 ,于用药前及用药后 3 0、60min和 2、 4、 6、 8、 12、 2 4h各测量眼压 1次 ,两组用药前后眼压、组间各时间点眼压进行对比分析。对 60例 (60眼 )原发性开角型青光眼病人 ,平行随机分为两组 ,一组使用 0 5 %马来酸洛尔 (Timolol)每日 2次点眼 ,另一组使用Trusopt每日 3次点眼 ,疗程 3周 ,分别于用药前及用药后 1、 2、 4、 7、 14、 2 1天固定时间测量眼压 1次 ,两组用药前后眼压、组间各时间点眼压进行对比分析。结果 :正常眼用药组平均眼压从用药后 3 0min开始下降 ,下降峰值出现在用药后 2小时 ,平均下降率 2 3 4% ,12小时后眼压下降 9 9% ,2 4小时眼压基本恢复到用药前水平。原发性开角型青光眼病人 ,两组用药前后眼压均有降低 (P <0 0 5 ) ,组间各时间点眼压均无明显差异 (P >0 0 5 )。Trusopt未见明显副作用。结论 :Trusopt有降低正常眼及原发性开角型青光眼病人眼压的作用 ,其作用与 0 5 %Timolol相近 ,它克服了CAI全身长期用药的副作用 ,可能成为早期原发性开角型青光眼病人的首选药物

The effects of Trusopt for glaucoma

To observe the clinical effect of Trusopt (2% dorzolamide) that was the first eye drops of carbonic anhydrase inhibitor (CAI) in glaucoma therapy. Methods:30 healthy volunteers (30 right eyes) were randomly divided into two groups,60 patients (60 eyes) with open angle glaucoma as volunteers were also divided into two groups,to receive 0 9% NS and Trusopt in the two normal groups and 0 5% timolol twice daily or Trusopt three times daily for three weeks in the two treated groups,respectively.Intraocular pressure (IOP) was taken pre and at 30,60 min.2,4,6,8,12,24 hours for the two normal groups,and 1,2,4,7,14,21 days after the eye drop instillation for the two treated groups,all was checked at the same time of each day.The results of IOPs were compared with baseline IOP of group itself,also with the other group on the same time point. Results:The IOP decreased from 30 min.after instillation in normal subjects.Maximal lowering of IOP was recorded at 2 hours point.On average,after 12 hours IOP was 9 9% lower than initial data.Till 24 hours,IOP returned to initial line.In the two treated groups,at three weeks,IOPs were both fallen down than the baseline (P<0 05),but the differences between the two groups were not significant at any time point (P>0 05).There was no obvious side effect of Trusopt.Conclusions:Trusopt seems as the same as Timolol on lowering the IOP.Since long term use of Trosopt was not associated with side effects observed clinically,the side effects of oral carbonic anhydrase inhibitors seems able to be avoided by Trusopt.It is likely that,therefore,Trusopt become the first choice for the medication of newly diagnosed open angel glaucoma.